Long‐term effect of oral cannabidiol administration to healthy adult dogs on tear production, intraocular pressure, and tear concentrations
Haley E. Jost, Katya Spitznagel, Isabella Corsato Alvarenga, Jaqueline Peraza, Krista Banks, Stephanie McGrath, Michala de Linde Henriksen- General Veterinary
Abstract
Objective
To determine the chronic effects of oral cannabidiol (CBD) use on tear production, intraocular pressure (IOP), and concentration of CBD in tears of healthy dogs.
Animals Studied
Eighteen healthy research Beagles.
Procedures
This was a masked, placebo‐controlled, randomized prospective study. Eighteen dogs were randomly assigned to three groups (six dogs per group) based on daily dosage of oral MCT oil (placebo), CBD 5 mg/kg, and CBD 10 mg/kg. Schirmer tear test (STT‐1) and IOP were measured twice daily (7 am and 7 pm) every 4 weeks for 36 weeks. Week 36 tears were collected and analyzed for CBD concentrations (ng/mL) using liquid chromatography/mass spectrometry. A mixed linear model was used as the statistical method and p‐value <.05 was considered significant.
Results
No significant differences were found between placebo vs. 5 mg/kg vs. 10 mg/kg for STT‐1 or IOP (AM and PM). CBD was detected in 10 out of 11 (91%) viable tear samples receiving 5 mg/kg or 10 mg/kg dosages. One sample in the 5 mg/kg group had inadequate tear volume for analysis. The CBD concentration in tears was at or below the lower limit of quantification in placebo group, 4.12–11.2 ng/mL for the 5 mg/kg group, and 6.22–152 ng/mL for the 10 mg/kg group.
Conclusions
Long‐term administration of oral CBD in healthy research beagles demonstrates a favorable safety profile regarding ocular tolerability. Oral CBD administration does not appear to affect tear production or IOP over a 36‐week period. This is the first canine study positively identifying concentrations of CBD in tears following oral administration.